By: Laura Curtin | Posted on: 18 Apr 2019

Careers in Biopharma – Keeping ahead of the Curve

The Irish Biopharma sector is booming, turning Ireland Inc into a thriving biopharma cluster with a constant thirst for talent.  With over 20 biologics manufacturing sites, and $10 billion in capital investment over the past ten years, the sector is forecast to add 8,400 new jobs up to 2020. 


In order to understand what developments are taking place in the sector and how best to adapt to the changing dynamics, Fastnet – The Talent Group® collaborates with the IDA, Enterprise Ireland, BPCI and the National Institute for Bioprocessing Research and Training (NIBRT). 


A great example of this collaboration is our recent involvement with NIBRT’s sixth annual ‘Careers in Biopharma’ event on April 13th, 2019.  Over 500 participants attended this renowned industry event.  Our Talent Consultants were very busy engaging with a cross section of individuals all interested in pursuing and elevating their career in the Life Science sector.  There was a lot of interest in our tips on CV optimisation and interview preparation, understanding how a recruitment agency can help with career development, and learning about career opportunities.  


The event afforded us an opportunity to meet with some of the main players in the expanding biopharma industry including AbbVie, Allergan, Amgen, Bristol-Myers Squibb J&J, MSD and Wuxi Biologics.  Also, it was a good way to catch up with clients on the day.


Our colleague Therese Keohane, Quality & Laboratory Lead, delivered a presentation on 'The Biopharma Industry - Staying Ahead of the Curve'.  She gave a good insight into the Biopharma industry, highlighted what is required for job hunting in digital age, and outlined the changes in recruitment practices and the increased use of psychometric testing.   



There is no doubt that it is an exciting time for us all supporting the Life Sciences sector.

More News

By using this website, you consent to the use of cookies in accordance with the privacy policy Ok, got it